Brokerages Set Fortress Biotech Inc (FBIO) Price Target at $11.00

Fortress Biotech Inc (NASDAQ:FBIO) has been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.00.

FBIO has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Fortress Biotech in a research report on Tuesday, December 5th. Zacks Investment Research cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. Finally, ValuEngine cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

In other news, CEO Lindsay A. Md Rosenwald bought 40,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $25.00 per share, with a total value of $1,000,000.00. Following the transaction, the chief executive officer now directly owns 40,000 shares in the company, valued at $1,000,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP George Avgerinos sold 12,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $3.55, for a total value of $42,600.00. Following the sale, the senior vice president now directly owns 352,495 shares of the company’s stock, valued at $1,251,357.25. The disclosure for this sale can be found here. 33.30% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. Strs Ohio lifted its position in Fortress Biotech by 301.4% during the 3rd quarter. Strs Ohio now owns 138,900 shares of the biopharmaceutical company’s stock worth $613,000 after acquiring an additional 104,300 shares during the period. State of Wisconsin Investment Board acquired a new stake in Fortress Biotech during the 2nd quarter worth approximately $119,000. Geode Capital Management LLC lifted its position in Fortress Biotech by 3.2% during the 1st quarter. Geode Capital Management LLC now owns 288,566 shares of the biopharmaceutical company’s stock worth $1,067,000 after acquiring an additional 8,958 shares during the period. Citadel Advisors LLC acquired a new stake in Fortress Biotech during the 3rd quarter worth approximately $101,000. Finally, Parametric Portfolio Associates LLC lifted its position in Fortress Biotech by 3.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 59,224 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 1,913 shares during the period. 12.05% of the stock is owned by institutional investors.

Fortress Biotech (NASDAQ FBIO) traded up $0.01 during trading hours on Tuesday, hitting $4.20. The stock had a trading volume of 153,148 shares, compared to its average volume of 167,250. The firm has a market cap of $212.25, a PE ratio of -2.31 and a beta of 1.11. Fortress Biotech has a twelve month low of $2.19 and a twelve month high of $5.13. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.42.

Fortress Biotech (NASDAQ:FBIO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.24). The business had revenue of $46.89 million for the quarter, compared to analyst estimates of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The firm’s quarterly revenue was up 4709.2% on a year-over-year basis. research analysts forecast that Fortress Biotech will post -1.99 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3127721/brokerages-set-fortress-biotech-inc-fbio-price-target-at-11-00.html.

About Fortress Biotech

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.